Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.370
+0.060 (1.39%)
At close: Aug 13, 2025, 4:00 PM
4.360
-0.010 (-0.23%)
After-hours: Aug 13, 2025, 4:06 PM EDT
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $52.59M in the quarter ending June 30, 2025, with 4.19% growth. This brings the company's revenue in the last twelve months to $203.47M, up 11.78% year-over-year. In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth.
Revenue (ttm)
$203.47M
Revenue Growth
+11.78%
P/S Ratio
1.24
Revenue / Employee
$552,899
Employees
368
Market Cap
258.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VNDA News
- 13 days ago - Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results - PRNewsWire
- 21 days ago - Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PRNewsWire
- 3 months ago - Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - PRNewsWire
- 3 months ago - Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - PRNewsWire